This Buccal drug delivery report provides detailed analysis of the market structure along with forecast for next Six years of the various segments and sub segments of the global market. Factors affecting the market growth based on various tools such as SWOT analysis and Porters Five Forces Analysis are also mentioned in this research report. It includes country level analysis of the market with respect to the current market size and future prospective. Moreover, this report tracks and analyzes the competitive development such as joint ventures, strategic alliances, mergers and acquisitions, etc. It covers emerging markets, business intelligence data, competitive landscape and opportunities and challenges faced by the industry.
Buccal drug delivery is alternative method of oral drug administration in which drug is delivered through buccal mucosa of oral cavity. The drug is usually placed between the upper gums and cheeks to treat various condition and disease. Additionally, buccal drug delivery is preference more compared to other conventional route of administration. The drugs delivered via buccal route are designed to provide sustained release of active ingredients.
Global Buccal drug delivery market is rising gradually with a substantial CAGR in the forecast period of 2019-2026. High demand of buccal drug delivery for ease of drug administration and new products launches are the key factors for market growth.
Comprehensive and Exclusive study of the Global Buccal drug delivery market at https://databridgemarketresearch.com/request-a-sample/?dbmr=global-buccal-drug-delivery-market
According to the statistics published in Alcohol and Drug Foundation, it is estimated up to 37.7% of people aged 14 years and above have used tobacco in the Australia. These growing cases of nicotine consumptions where buccal drug delivery is predominant intervention and high demand of novel therapies are the key drivers for market growth.
Few of the major competitors currently working in the global buccal drug delivery market : Teva Pharmaceutical Industries Ltd, Pfizer Inc, Cynapsus, BioDelivery Sciences International, Inc, GlaxoSmithKline plc, MedLab, AstraZeneca, F. Hoffmann-La Roche Ltd, Dr. Reddy’s Laboratories Ltd, Sanofi, Generex Biotechnology Corp, Bayer AG, Takeda Pharmaceutical Company Limited, Novartis AG, Indivior PLC, Novo Nordisk A/S, NAPP PHARMACEUTICALS LIMITED, Endo Pharmaceuticals Inc and many others.
Increase demand of buccal drug delivery for ease of drug administration is propelling the market growth
Growing preference of buccal drug delivery over conventional drug delivery method acts as a market driver
Rapid adoption of newer formulations and novel dosage forms can boost the market growth
Application of latest technologies in the health care industry can also act as a market driver
Scientific and major technical challenges for developing the drugs to be administered via buccal will hamper the market growth
High cost involved in research and development for novel formulation is restricting the growth of the market
Patent expiry of major drugs and introduction of generic drugs of branded version is expected to restrict the growth of this market
Recent Key Developments:
In February 2019, Sandoz, a subsidiary of Novartis AG launched generic version of suboxone (buprenorphine and naloxone), sublingual film for the treatment of opioid dependence. The launchof buprenorphine and naloxone has expanded the company’s generic portfolio in the therapeutic area of psychology
In February 2016, BioDelivery Sciences International, Inc and their distributer partner Endo Pharmaceuticals Inc has launched Belbuca (buprenorphine), buccal film for the treatment of severe pain. The launch of Belbuca provides an important new alternative treatment for individuals suffering from chronic pain throughout the world
Advantages of Buccal Drug Delivery Systems
- Termination of therapy is possible
- Permits localization of drug to the oral cavity for extended period of time.
- Ease of administration
- Avoids first pass metabolism.
- Reduction in dose can be achieved, thereby reducing dose dependent side effects
- It allows local modification of tissue permeability, inhibition of protease activity or reduction in immunogenic response, thus selective use of therapeutic agents like peptides, proteins and ionized species can be achieved.
- Drugs which are unstable in acidic environment of stomach or destroyed by the alkaline environment of intestine can be given by this route
Key Segmentation of Buccal Drug Delivery Market
Non-Attached Drug Delivery Systems
Bio-Adhesive Drug Delivery Systems
By Dosage Forms
Solid Buccal Adhesive Dosage Forms
Semi-Solid Buccal Adhesive Dosage Forms
Liquid Buccal Adhesive Dosage Forms
Oral Bioadhesive Formulation
Middle East & Africa
About Data Bridge Market Research:
An absolute way to forecast what future holds is to comprehend the trend today!
Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.
Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.
Data Bridge Market Research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475